SCHEMBL5135936

SCHEMBL5135936

CCCCN(Cc1ccc2c(c1)OCCO2)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.63
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TSHR P16473 3/20 0.37
GBA1 P04062 1/20 0.37
PTGDR2 Q9Y5Y4 2/20 0.36
BCHE P06276 1/20 0.36
CYP2C8 P10632 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 3/20 0.36
HSD17B10 Q99714 3/20 0.36
MAPT P10636 1/20 0.36
CRHR1 P34998 2/20 0.36
CYP3A4 P08684 2/20 0.35
GNRHR P30968 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5071329 0.97 C5AR1 (0.60) C5AR1SMN1; SMN2LMNAL3MBTL1TSHR
SCHEMBL5135734 0.96 C5AR1 (0.63) C5AR1SMN1; SMN2LMNAL3MBTL1TSHR
SCHEMBL5136554 0.96 C5AR1 (0.58) C5AR1SMN1; SMN2LMNAL3MBTL1TSHR
SCHEMBL1912839 0.95 C5AR1 (0.66) C5AR1SMN1; SMN2LMNAL3MBTL1TSHR
SCHEMBL5073846 0.95 C5AR1 (0.58) C5AR1SMN1; SMN2LMNAL3MBTL1TSHR
SCHEMBL5136601 0.95 C5AR1 (0.58) C5AR1SMN1; SMN2LMNAL3MBTL1GBA1
SCHEMBL5137882 0.94 C5AR1 (0.71) C5AR1SMN1; SMN2LMNAL3MBTL1TSHR
SCHEMBL650546 0.94 C5AR1 (0.59) C5AR1SMN1; SMN2LMNAL3MBTL1TSHR
SCHEMBL4765639 0.94 C5AR1 (0.64) C5AR1SMN1; SMN2LMNAL3MBTL1TSHR
SCHEMBL5135701 0.94 C5AR1 (0.64) C5AR1SMN1; SMN2LMNAL3MBTL1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed